Simple view
Full metadata view
Authors
Statistics
Current management and future perspectives of overactive bladder (OAB) pharmacotherapy
overactive bladder
OAB current pharmacotherapy
antimuscarinics
OAB future pharmacotherapy
Bibliogr. s. 820-821
Overactive bladder (OAB) is a condition characterized by urgency with or without urgency incontinence (UI), usually with increased daytime frequency and nocturia, which affects even 8-14% of adult population. The gold standards of OAB treatment are antimuscarinics, although this clinical entity is often poorly controlled with these agents. Thus, a progress in OAB pharmacotherapy is expected and takes place. The purpose of this article is to short review the present management of the overactive bladder with paying special attention on development of new drugs indicated for OAB treatment.
dc.abstract.en | Overactive bladder (OAB) is a condition characterized by urgency with or without urgency incontinence (UI), usually with increased daytime frequency and nocturia, which affects even 8-14% of adult population. The gold standards of OAB treatment are antimuscarinics, although this clinical entity is often poorly controlled with these agents. Thus, a progress in OAB pharmacotherapy is expected and takes place. The purpose of this article is to short review the present management of the overactive bladder with paying special attention on development of new drugs indicated for OAB treatment. | pl |
dc.affiliation | Wydział Lekarski : Zakład Patofizjologii | pl |
dc.contributor.author | Dobrek, Łukasz - 129181 | pl |
dc.contributor.author | Juszczak, Kajetan - 162229 | pl |
dc.contributor.author | Wyczółkowski, Marek | pl |
dc.contributor.author | Thor, Piotr - 133660 | pl |
dc.date.accession | 2020-07-28 | pl |
dc.date.accessioned | 2020-07-28T10:50:58Z | |
dc.date.available | 2020-07-28T10:50:58Z | |
dc.date.issued | 2011 | pl |
dc.date.openaccess | 0 | |
dc.description.accesstime | w momencie opublikowania | |
dc.description.additional | Bibliogr. s. 820-821 | pl |
dc.description.number | 6 | pl |
dc.description.physical | 807-821 | pl |
dc.description.publication | 1,55 | pl |
dc.description.version | ostateczna wersja wydawcy | |
dc.description.volume | 68 | pl |
dc.identifier.eissn | 2353-5288 | pl |
dc.identifier.issn | 0001-6837 | pl |
dc.identifier.project | ROD UJ / OP | pl |
dc.identifier.uri | https://ruj.uj.edu.pl/xmlui/handle/item/242916 | |
dc.identifier.weblink | https://www.ptfarm.pl/wydawnictwa/czasopisma/acta-poloniae-pharmaceutica/110/-/13701 | pl |
dc.language | eng | pl |
dc.language.container | eng | pl |
dc.rights | Udzielam licencji. Uznanie autorstwa - Użycie niekomercyjne 4.0 Międzynarodowa | * |
dc.rights.licence | CC-BY-NC | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/legalcode.pl | * |
dc.share.type | otwarte czasopismo | |
dc.subject.en | overactive bladder | pl |
dc.subject.en | OAB current pharmacotherapy | pl |
dc.subject.en | antimuscarinics | pl |
dc.subject.en | OAB future pharmacotherapy | pl |
dc.subtype | Article | pl |
dc.title | Current management and future perspectives of overactive bladder (OAB) pharmacotherapy | pl |
dc.title.journal | Acta Poloniae Pharmaceutica. Drug Research | pl |
dc.type | JournalArticle | pl |
dspace.entity.type | Publication |
* The migration of download and view statistics prior to the date of April 8, 2024 is in progress.
Views
19
Views per month
Views per city
Downloads
Open Access